Gokul M Das

9PUBLICATIONS
27CO-AUTHORS
Molecular targetsCancer geneticsCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Nov 07, 2026
Tamoxifen and Doxorubicin Synergistically Target Estrogen Receptor β-Mutant p53-p73 Axis, a Therapeutically Actionable Vulnerability in Triple Negative Breast Cancer.

|Jul 28, 2026
Correction: Oturkar et al. Estrogen Receptor-Beta2 (ERβ2)-Mutant p53-FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC). Cancers 2022, 14, 1120.

|Jul 17, 2025
Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in Black American and White American patients with TNBC.

Qian Zhu, Akhila Balasubramanian, Jaya Ruth Asirvatham

|Feb 01, 2025
Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen?

Gokul M Das, Chetan C Oturkar, Vishnu Menon

|Mar 08, 2023
Immature natural killer cells promote progression of triple-negative breast cancer.

Gatha Thacker, Samantha Henry, Ajeya Nandi

|Feb 11, 2023
Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53.

Lauren Scarpetti, Chetan C Oturkar, Dejan Juric

Pageof 2

Frequent Collaborators

2 joint publications

Chetan C Oturkar

2 joint publications

Kevin H Eng

2 joint publications

Austin Miller

2 joint publications

Emese Zsiros